Aethlon Medical Begins First Clinical Study of Hemopurifier for HIV Treatment
Posted on: Tuesday, 30 September 2008, 09:00 CDT
Aethlon Medical, a developmental-stage medical device company, has initiated patient enrollment in the first-in-man clinical study of a medical device to treat the human immunodeficiency virus, the disease that causes acquired immune deficiency syndrome.
The human immunodeficiency virus (HIV) treatment studies are being conducted at the Jattinder Gambhir Hospital in Punjab, India, and the Bhvani Hospital in Bihar, India. In the studies, up to six HIV-infected patients will be administered daily Hemopurifier treatment for a period up to nine consecutive days.
The device, known as the Aethlon Hemopurifier, assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. The Hemopurifier has previously demonstrated rapid viral load reduction in hepatitis-C patients, and based on research data, is said to be the most advanced broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats.
In HIV care, the Hemopurifier is designed to provide both an antiviral and immunotherapeutic mechanism of action. The goal of treatment is to inhibit viral replication through the rapid clearance of all strains of infectious HIV, and to augment the immune response by eliminating circulating gp120, a protein that sheds from the surface of HIV to kill-off immune cells necessary to fight infection, the company said.
Jim Joyce, Aethlon chairman and CEO, said: "Based on our recent hepatitis-C treatment observations, I am increasingly confident that our Hemopurifier will demonstrate similar effectiveness in HIV studies. If correct, the Hemopurifier will advance HIV care by offering a treatment option that extends life for patients no longer responsive to drug therapy, and enhances the benefit of drug regimens by inhibiting the proliferation of HIV strains that cause drug resistance."
Source: Datamonitor
Related Articles
- Early HIV treatment can reduce death rates
- Early HIV Treatment Radically Boosts Survival
- AHF Blasts GlaxoSmithKline Print Ads That Promote Fear of HIV Treatment
- Karolinska Hospital to Become First in Sweden to Offer Advanced RapidArc Cancer Treatments From Varian Medical Systems
- India to Increase HIV Treatment Centers
- Drug Maker Cites 2 More Patient Deaths
- Trial Shows New Drug May Help Cancer Patients Who Need Stem Cell Transplants
- New Study Results Find That Patients Treated With Boosted INVIRASE, A Potent Anti-HIV Treatment, Showed No Significant Resistance to Protease Inhibitors
- The Potential Benefits Outweigh Concerns Over Drugs Catered to Specific Patients
- Patient Deaths Decline in Early Studies of New Cancer Drugs More-Targeted Drugs, More Emphasis on Patient Safety Cited in Minimizing Risk
 |
 |
User Comments (0)
RSS Feeds